Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 3/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28905992 | 1.00 | P2RX7 (0.65) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Hydrochloric Acid SCHEMBL5010797 | 0.98 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Fluoride SCHEMBL22032488 | 0.98 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Ammonia Solution, Strong SCHEMBL28560460 | 0.98 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Hydrochloric Acid SCHEMBL3086243 | 0.98 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL28331539 | 0.98 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL22032484 | 0.94 | P2RX7 (0.59) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| Cyanide SCHEMBL28204544 | 0.94 | P2RX7 (0.59) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL29082826 | 0.93 | P2RX7 (0.62) | P2RX7PARP1MKNK1MKNK2RAB9A | |
| SCHEMBL22032483 | 0.91 | P2RX7 (0.56) | P2RX7PARP1MKNK1MKNK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1697 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106725-A1 | CHLOROPHYLL DERIVATIVES, CAROTENOID DERIVATIVES, AND DIETARY SUPPLEMENTS FOR HUMAN OCULAR HEALTH AND VISUAL PERFORMANCE | RETINABIO, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4580589-A1 | USE OF A COMPOSITION FOR BOOSTING SKIN'S NIGHT REPAIR ASSOCIATED FUNCTIONS | Unilever IP Holdings B.V. (NL) | 2025-07-09 | — | — | EP | claimed |
| EP-4577545-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2025-07-02 | — | — | EP | claimed |
| US-20250161201-A1 | COSMETIC COMPOSITION | THE BOOTS COMPANY PLC (GB) | 2025-05-22 | — | — | US | claimed |
| US-12281094-B2 | Preparation method of racemic nicotine | SHENZHEN ZINWI BIO-TECH CO., LTD (CN) | 2025-04-22 | — | — | US | claimed |
| CN-119654130-A | Use of a composition for enhancing night repair related functions of skin | 联合利华知识产权控股有限公司 | 2025-03-18 | — | — | CN | claimed |
| EP-4501928-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | Autotelic Bio Inc. (KR) | 2025-02-05 | — | — | EP | claimed |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | HK INNO.N CORPORATION (KR) | 2024-12-31 | — | — | US | claimed |
| CN-119110720-A | Cosmetic composition | 布茨公司 | 2024-12-10 | — | — | CN | claimed |
| US-20240390256-A1 | A DEODORANT COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2024-11-28 | — | — | US | claimed |
| WO-2001078648-A2 | 6-METHYLNICOTINAMIDE DERIVATIVES AS ANTIVIRAL AGENTS | DONG WHA PHARM. IND. CO., LTD. (KR) | 2001-10-25 | — | — | WO | claimed |
| EP-1123039-A1 | METHOD FOR NON-INVASIVE BLOOD ANALYTE MEASUREMENT WITH IMPROVED OPTICAL INTERFACE | Rio Grande Medical Technologies, Inc. (US) | 2001-08-16 | — | — | EP | claimed |
| US-6240306-B1 | Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration | RIO GRANDE MEDICAL TECHNOLOGIES, INC. | 2001-05-29 | — | — | US | claimed |
| WO-2001001852-A1 | METHOD AND APPARATUS FOR NON-INVASIVE BLOOD ANALYTE MEASUREMENT | RIO GRANDE MEDICAL TECHNOLOGIES, INC. (US) | 2001-01-11 | — | — | WO | claimed |
| US-6152876-A | Method for non-invasive blood analyte measurement with improved optical interface | RIO GRANDE MEDICAL TECHNOLOGIES, INC. (US) | 2000-11-28 | — | — | US | claimed |
| EP-1017390-A2 | COMBINATIONS OF HMG-COA INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 2000-07-12 | — | — | EP | claimed |
| WO-2000022982-A1 | METHOD FOR NON-INVASIVE BLOOD ANALYTE MEASUREMENT WITH IMPROVED OPTICAL INTERFACE | RIO GRANDE MEDICAL TECHNOLOGIES, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-5872104-A | BACTERICIDES AND RESISTANT BACTERIA WITH METHYLATION INHIBITORS | ORIDIGM CORPORATION (US) | 1999-02-16 | — | — | US | claimed |
| WO-1999006035-A2 | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281094-B2 | Preparation method of racemic nicotine | NNMT, NAPRT, ADH1C | P2RX7 2932/4885PARP1 1878/4885MKNK1 2769/4885 |
| US-20250161201-A1 | COSMETIC COMPOSITION | CYP19A1, SHBG, HSD17B11 | P2RX7 2831/4885PARP1 4749/4885MKNK1 2346/4885 |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | MAP3K20, MAP3K1, MAP3K15 | P2RX7 2697/4885PARP1 1984/4885MKNK1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.